Introduction: In 2021, a biotech company was developing a vaccine that needed large scale oligonucleotide production capacity and rapid turnaround to produce hundreds of kilo oligonucleotide adjuvant. From May 2021 to September 2022, in 16 months with COVID interruptions, WuXi TIDES completed the technology transfer and delivered over 400kg of oligonucleotide product, as well as Process Performance Qualification (PPQ) enabling and PPQ campaign. Moreover, WuXi TIDES developed a robust commercial supply chain to support large-scale oligonucleotide manufacturing.
Privacy Overview
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.